MX2022015336A - Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares. - Google Patents

Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.

Info

Publication number
MX2022015336A
MX2022015336A MX2022015336A MX2022015336A MX2022015336A MX 2022015336 A MX2022015336 A MX 2022015336A MX 2022015336 A MX2022015336 A MX 2022015336A MX 2022015336 A MX2022015336 A MX 2022015336A MX 2022015336 A MX2022015336 A MX 2022015336A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
cardiovascular diseases
hyperlipidaemia
fibrates
Prior art date
Application number
MX2022015336A
Other languages
English (en)
Inventor
Canudas Jorge Alejandro González
Salazar Claudia Delfina Farfán
León Sixto Serafín Espinoza
Rubio Paola Yazmín Ollervides
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of MX2022015336A publication Critical patent/MX2022015336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presenta invención combina en una sola unidad de dosificación los fármacos atorvastatina y fenofibrato el cual representa un conjunto de importantes retos tecnológicos debido a las propiedades fisicoquímicas y a la diferencia en dosis para garantizar la obtención de un producto estable en el tratamiento de hiperlipidemias y prevención de enfermedades cardiovasculares.
MX2022015336A 2020-09-29 2020-09-29 Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares. MX2022015336A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050034 WO2022071787A1 (es) 2020-09-29 2020-09-29 Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares

Publications (1)

Publication Number Publication Date
MX2022015336A true MX2022015336A (es) 2023-01-11

Family

ID=80951574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015336A MX2022015336A (es) 2020-09-29 2020-09-29 Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.

Country Status (11)

Country Link
US (1) US20230355578A1 (es)
EP (1) EP4180036A4 (es)
JP (1) JP2023543565A (es)
KR (1) KR20230079187A (es)
BR (1) BR112023005247A2 (es)
CA (1) CA3191478A1 (es)
CO (1) CO2023004367A2 (es)
DO (1) DOP2023000043A (es)
MX (1) MX2022015336A (es)
PE (1) PE20240141A1 (es)
WO (1) WO2022071787A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CN100551363C (zh) * 2003-10-10 2009-10-21 生命周期药物公司 包含贝特的固体剂型
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
EP1804769A1 (en) 2004-10-01 2007-07-11 LifeCycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
CN101115478A (zh) * 2005-02-10 2008-01-30 生命周期药物公司 包含非诺贝特和HMG-CoA还原酶抑制剂的固定剂量组合的稳定药物组合物
BRPI0606883A2 (pt) * 2005-02-10 2009-12-01 Lifecycle Pharma As composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
EP1818049A3 (en) * 2006-02-10 2008-11-19 LifeCycle Pharma A/S Stabilized Atorvastatin
JP2011526621A (ja) 2008-07-03 2011-10-13 パナセア バイオテック リミテッド 経口バイオアベイラビリティが増大したフェノフィブラート製剤
EP2341773A4 (en) 2008-09-24 2012-03-07 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
CN102188419A (zh) * 2010-03-12 2011-09-21 上海天龙药业有限公司 包含非诺贝特和阿托伐他汀的单个制剂
US20140335179A1 (en) 2011-07-01 2014-11-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
MX2013006332A (es) 2013-06-05 2014-12-19 Alparis Sa De Cv Composiciones farmaceuticas orales para uso en dislipidemias.
BR102013028912A2 (pt) * 2013-11-08 2017-02-14 Hypermarcas S A composição farmacêutica, forma farmacêutica oral, cápsula, comprimido de dupla camada, usos, método de tratamento de hipercolesterolemia, hipertrigliceridemia e/ou dislipidemia mista e método de prevenção de aterosclerose, diabetes ou prevenção secundária de outras doenças cardiovasculares

Also Published As

Publication number Publication date
WO2022071787A1 (es) 2022-04-07
JP2023543565A (ja) 2023-10-17
BR112023005247A2 (pt) 2023-04-25
PE20240141A1 (es) 2024-02-01
CA3191478A1 (en) 2022-04-07
CO2023004367A2 (es) 2023-05-29
EP4180036A4 (en) 2024-01-31
KR20230079187A (ko) 2023-06-05
DOP2023000043A (es) 2023-04-30
EP4180036A1 (en) 2023-05-17
US20230355578A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CY1120088T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
NO20092321L (no) Doserings- og drivmekanisme for legemiddelleveringsanordning
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
NO20092323L (no) Doserings- og drivmekanisme for legemiddelleveringsanordning
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
CY1107389T1 (el) Σελεκοξιμπη σε μορφη στερεης καταστασης με ενισχυμενη βιοδιαθεσιμοτητα
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
NZ604662A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
MY160732A (en) A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol
PH12021550237A1 (en) Bioavailable oral dosage forms.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2022005813A (es) Formas de dosificacion novedosas de rofecoxib y métodos relacionados.
MX2022015336A (es) Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.
EP4218765A3 (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
RU2012131959A (ru) Способ лечения остеоартрита
EP4238556A4 (en) GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM
EA202190317A1 (ru) Лекарственный препарат для наружного применения
DE60041281D1 (de) Stabilisiertes arzneimittel und arzneizubereitung
MX2023012745A (es) Composicion farmaceutica de pembrolizumab y su uso.
EA202191124A1 (ru) Лекарственная форма для лечения и профилактики гриппа и орви
EA202092999A1 (ru) Противовирусная композиция
MX2024001039A (es) Combinacion para usarse en el tratamiento de la hipercolesterolemia, la hiperlipidemia, la enfermedad cardiovascular y el sindrome metabolico.
Bezditko et al. Pharmacoepidemiological analysis: dynamics of availability of statins in Ukraine